Contact Us

Service Line:+1-315-239-3085

Address:FL-4, Building A5, International Enterprise Community, Tianjin, China

Email:info@kmdbioscience.com

Online Inquery

  •   
  •   
  •   
  • Refresh

Native Inactivated COVID-19/SARS-CoV-2  Antigen

Product Information
Catalog Number COV367
Product Name Native Inactivated COVID-19/SARS-CoV-2  Antigen
Alias 2019-nCoV virus, Native COVID-19 antigen
Size 100μg,500μg
Species COVID-19/2019-nCoV
Expression Host Vero cell
Applications Immunogen, WB, ELISA, POCT
Purity ≥95% as determined by SDS-PAGE
Endotoxin < 0.1EU per μg protein as determined by the LAL method.
Biological Activity Immobilized mouse anti-2019-nCoV monoclonal antibody (Cat.#: MAV109) at 2μg/ml (100 μl/well) can bind 2019-nCoV native antigen (Cat.#: COV367). 
Buffer 0.01M PBS, pH7.4
Purification IEX & SEC-HPLC
Background The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue. As of 11 February 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China. On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern. SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough. Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest. The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clinical trial in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used. However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond.
Storage Store the lyophilized powder at 4°C for one week and -20°C to -80°C for long time. Store the liquid form at -80°C. Avoid multiple freeze/thaw cycles.
Shipping Condition Dry ice or ice packs. 
Note This product is used for research use only. Not for human or diagnostic use.